On September 27, 2022 LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, reported the recipients of their 2022 Career Development Awards (Press release, LUNGevity Foundation, SEP 27, 2022, View Source [SID1234621487]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

LUNGevity’s Career Development Awards (CDA), now in their 11th consecutive year, support a cohort of future research leaders who will keep the pipeline of lung cancer research energized with new ideas and novel approaches. Awardees receive funding for their research projects, coveted mentorship opportunities, and serve as non-voting members of LUNGevity’s Scientific Advisory Board for the term of the awards. They also receive training in effective science communications.

"It’s a privilege to announce the 2022 class of LUNGevity Career Development Awardees. As we just completed a systematic analysis of the lung cancer treatment landscape, we are confident these CDAs will address key unmet needs in the treatment landscape—developing immunotherapy combination approaches in the treatment of early-stage and metastatic non-small cell lung cancer, and new treatment options for rare lung cancers." says Upal Basu Roy, PhD, MPH, Executive Director of Research at LUNGevity. "By funding these early career researchers, LUNGevity helps to retain promising scientists in the lung cancer space. The CDA program encourages their continued focus on the key challenges facing the lung cancer community and contributes to a robust pipeline of dedicated lung cancer researchers."

Past recipients of these awards have developed their own independent research programs, received major grants from the NIH and other funders, and even succeeded in getting a new treatment approved by the FDA. This year, the recipients of this prestigious award are:

Kristen Marrone, MD
Johns Hopkins School of Medicine
Project: Phase 2 trial of neoadjuvant KRAS G12C directed therapy in resectable NSCLC

Dr. Marrone will conduct a phase 2 clinical trial to test whether treatment with a KRAS G12C blocking drug, adagrasib, given as a single drug or in combination with an immunotherapy drug, nivolumab, before a patient undergoes surgery, can delay or prevent recurrence in patients with early-stage non-small cell lung cancer (NSCLC) whose tumors have a KRAS G12C mutation.

Michael Offin, MD
Memorial Sloan Kettering Cancer Center
Project: Therapeutic targeting of BRAF fusion altered lung cancer

Dr. Offin will be testing a series of new drugs in pre-clinical cell lines and animal models of lung cancer that contain BRAF fusions, which are known to be powerful stimulators of lung cancer development. Currently no targeted treatment exists for cancers that harbor these BRAF fusions. The goal of this project is to identify new drugs for this unmet need that can be tested in clinical trials.

Joshua Reuss, MD
Georgetown University
Project: Combination checkpoint blockade plus VEGF inhibitor in EGFR-mutated NSCLC

Dr. Reuss is conducting a phase 2 clinical trial to test whether a regimen of two immunotherapy drugs, atezolizumab and tiragolumab, given in combination with a VEGF inhibitor, bevacizumab, is effective in controlling EGFR-positive NSCLC that has become resistant to osimertinib.

LUNGevity implements a rigorous process to carefully select awardees. Each research project is evaluated by a multidisciplinary review committee of thoracic oncology leaders, who are committed to finding lung cancer at its earliest, most treatable phase, as well as for extending and improving the lives of lung cancer survivors.

"Congratulations to these awardees. When they look back, years from now, I believe this support from LUNGevity is likely to be viewed as an important turning-point in their careers," said Charles Rudin, MD, PhD, Professor and Chief of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center and Chair of LUNGevity’s Scientific Advisory Board. "These exceptional young investigators are poised to bring tremendous growth and improvements in our treatment of lung cancer. And I’m proud that LUNGevity Foundation is catalyzing their progress. "

LUNGevity is the only lung cancer organization with a programmatic focus on early detection and a strong Career Development Award Program. LUNGevity-funded researchers are working on finding a better way to detect lung cancer, and to better diagnose, treat, and prevent its recurrence. The Foundation’s translational research program, including the CDA awards, seeks to move the science forward to improve outcomes for people living with lung cancer.

LUNGevity’s Career Development Awards program is supported by Genentech.